Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Patients who have undergone curative treatment may be at risk of relapse. This study will collect, annotate, and sequence biospecimens (blood, stool, and tissue) from patients across different tumor types to detect molecular residual disease (MRD) before metastases become radiographically or clinically detectable. This will allow for early cancer interception, and hopefully prolong relapse-free survival across tumor types.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjenci z potwierdzonym nowotworem złośliwym.
- •Pacjenci z rakiem we wczesnym stadium lub zaawansowanym miejscowo, którzy byli lub będą leczeni z intencją wyleczenia.
- •Pacjenci w wieku 18 lat lub starsi.
- •Pacjenci, którzy wyrazili świadomą zgodę na udział w badaniu.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 28, 2026
- Sex
- No restrictions
Locations (1)
Princess Margaret Cancer Centre
Toronto, Canada
Trial contact
Celeste Yu, MSc
Elizabeth Shah
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/29/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.